In this part of his Pharmaceutical Executive video interview, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses the biggest misconceptions about fertility that he sees circulating on social media and work he does to correct and prevent them.
In this Pharmaceutical Executive video interview, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses the challenges of addressing fertility misinformation on social media. He emphasizes the importance of providing accurate and reliable information and encourages patients to consult with healthcare professionals. He also discusses the ethical considerations of using social media to share personal and professional experiences in the field of fertility.
it's not an easy question to answer, Miranda. There are a lot of things that are packed into that comment. But let me start out by saying number one, I think that social media can be very, very beneficial in that it can impart an educational approach to fertility and fertility issues. On the flip side, you also know that there are many people who get on the social media, on TikTok, on Instagram, on whatever it may be, and tell stories that may or may not be factual.
Part of the problem that we deal with is that many times patients that we see come to us with questions that they've heard on TikTok or on Instagram or on Facebook or some social media aspect and are confused about what it really means. So, I think that the critical thing for us, and the thing that I typically do for me, is two things. Number one, when I meet with the patients, I try to give them an overview of what what goes on when they get evaluated by a fertility specialists and I try and explain to them what happens to them, what their evaluation is, what that evaluation means, and what their ultimate likelihood for success is depending on what they do.
The second thing I try to do is every Wednesday, at about 12:15pm I do a TikTok, which is called Wednesdays with the Werl. And when I do that TikTok, I effectively will pick a topic and will review that topic with the people who are involved on the TikTok, and then I open it up to questions. And maybe once a month, people have questions constantly. So once a month, I will actually do that Wednesdays with the world and only go through questions that people ask and try and answer them and give them the best answer that I can. I think the most important thing that I try to have patients take away from this is that one, it's educational, and two, what medicine is, is definitely a science.
But reproductive medicine is also an art, and how people do things can be different. My way of doing things is certainly my way of doing things, but it doesn't mean that it's the only way. There are other ways that you may approach a similar problem. It doesn't mean they're right or wrong. It just means that there are other ways to do things. And I think it's important, and I think it's important that when people go to these social media scenarios, that they take away from it, whatever it is they do, and then when they talk to their fertility physician — they can give them the pros and cons about what they ask. So, I think that's how hopefully I would try to approach it.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
June 13th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
June 13th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.
2 Commerce Drive
Cranbury, NJ 08512